应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
06990 科伦博泰生物
交易中 05-07 10:48:51
453.600
-6.000
-1.31%
最高
484.000
最低
448.800
成交量
12.20万
今开
465.600
昨收
459.600
日振幅
7.66%
总市值
1,057亿
流通市值
775.58亿
总股本
2.33亿
成交额
5,618万
换手率
0.07%
流通股本
1.71亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
港股异动 | 科伦博泰生物(06990)尾盘涨近3% 3项研究成果入选2026年ASCO年会口头汇报
智通财经 · 04-24
港股异动 | 科伦博泰生物(06990)尾盘涨近3% 3项研究成果入选2026年ASCO年会口头汇报
创新药概念持续拉升 海西新药(02637)领涨12.77%、歌礼制药-B(01672)涨6.27%
金吾财讯 · 04-24
创新药概念持续拉升 海西新药(02637)领涨12.77%、歌礼制药-B(01672)涨6.27%
汇添富基金张韡旗下汇添富创新医药一季报最新持仓，重仓科伦博泰生物
证券之星 · 04-22
汇添富基金张韡旗下汇添富创新医药一季报最新持仓，重仓科伦博泰生物
科伦博泰生物-B完成股份转换，新增8,214,278股H股
公告速递 · 04-17
科伦博泰生物-B完成股份转换，新增8,214,278股H股
科伦博泰生物(06990)完成H股全流通
智通财经 · 04-17
科伦博泰生物(06990)完成H股全流通
科伦博泰生物-B2025年研发投入达31亿元，收入稳步增长但亏损扩大
公告速递 · 04-16
科伦博泰生物-B2025年研发投入达31亿元，收入稳步增长但亏损扩大
中金：国家优化创新药新药上市首发价格机制 药品行业有望迎高质量发展
智通财经 · 04-16
中金：国家优化创新药新药上市首发价格机制 药品行业有望迎高质量发展
科伦博泰生物(06990)4月15日认购本金额为1亿元的浙商银行结构性存款II
智通财经 · 04-15
科伦博泰生物(06990)4月15日认购本金额为1亿元的浙商银行结构性存款II
国办一纸文件定调药价，创新药爆发！涨停名单还在拉长
格隆汇 · 04-15
国办一纸文件定调药价，创新药爆发！涨停名单还在拉长
科伦博泰生物公布Sacituzumab Tirumotecan妇科肿瘤研究结果，亮相2026年SGO年会
美股速递 · 04-14
科伦博泰生物公布Sacituzumab Tirumotecan妇科肿瘤研究结果，亮相2026年SGO年会
摘“B”成功：科伦博泰生物市值破千亿港元，4月14日起简称去掉“B”
财中社 · 04-09
摘“B”成功：科伦博泰生物市值破千亿港元，4月14日起简称去掉“B”
科伦博泰生物-B更新2026年3月股份变动月报表，股本维持稳定
公告速递 · 04-09
科伦博泰生物-B更新2026年3月股份变动月报表，股本维持稳定
科伦博泰生物-B(06990)H股全流通获联交所授出上市批准
智通财经 · 04-08
科伦博泰生物-B(06990)H股全流通获联交所授出上市批准
科伦博泰生物-B(06990)：中国证监会就公司H股全流通发出备案通知书
智通财经 · 03-27
科伦博泰生物-B(06990)：中国证监会就公司H股全流通发出备案通知书
【券商聚焦】西南证券维持科伦博泰生物-B(06990)“买入”评级 指
金吾财讯 · 03-27
【券商聚焦】西南证券维持科伦博泰生物-B(06990)“买入”评级 指
【券商聚焦】招银国际维持科伦博泰(06990)“买入”评级 指2025年为向商业化转型的关键之年
金吾财讯 · 03-25
【券商聚焦】招银国际维持科伦博泰(06990)“买入”评级 指2025年为向商业化转型的关键之年
高盛重申“买入”科伦博泰生物-B(06990)：芦康沙妥珠单抗OS数据表现突出 公司增长潜力持续释放
智通财经 · 03-24
高盛重申“买入”科伦博泰生物-B(06990)：芦康沙妥珠单抗OS数据表现突出 公司增长潜力持续释放
科伦博泰生物-B(06990)： SKB103新药临床试验申请获国家药品监督管理局批准
智通财经 · 03-24
科伦博泰生物-B(06990)： SKB103新药临床试验申请获国家药品监督管理局批准
科伦博泰生物-B SKB103新药临床试验申请获中国国家药监局批准用于晚期实体瘤
美股速递 · 03-24
科伦博泰生物-B SKB103新药临床试验申请获中国国家药监局批准用于晚期实体瘤
港股异动 | TSLP抗体疗法I期临床研究结果发表 科伦博泰生物-B(06990)涨超7% 和铂医药-B(02142)涨超4%
智通财经 · 03-24
港股异动 | TSLP抗体疗法I期临床研究结果发表 科伦博泰生物-B(06990)涨超7% 和铂医药-B(02142)涨超4%
加载更多
公司概况
公司名称：
科伦博泰生物
所属市场：
SEHK
上市日期：
--
主营业务：
四川科伦博泰生物医药股份有限公司是一家主要从事新药业务的研发、生产和销售的中国公司。该公司主要从事肿瘤学、免疫学及其他治疗领域的创新药物的研发、制造及商业化。该公司的产品有抗体药物偶联物（ADC）SKB264和A166等。该公司产品主要用于乳腺癌、非小细胞肺癌、胃肠道癌等疾病的治疗。
发行价格：
--
{"stockData":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科伦博泰生物","latestPrice":453.6,"timestamp":1778122097081,"preClose":459.6,"halted":0,"volume":122000,"delay":0,"changeRate":-0.013054830287206266,"floatShares":170984257,"shares":233000000,"eps":-1.9065813921978654,"marketStatus":"交易中","change":-6,"latestTime":"05-07 10:48:51","open":465.6,"high":484,"low":448.8,"amount":56177500,"amplitude":0.076588,"askPrice":453.6,"askSize":1400,"bidPrice":452.6,"bidSize":1600,"shortable":3,"etf":0,"ttmEps":-1.9065813921978654,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1778126400000},"marketStatusCode":2,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":459.6,"openAndCloseTimeList":[[1778117400000,1778126400000],[1778130000000,1778140800000]],"volumeRatio":1.744087,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06990","defaultTab":"news","newsList":[{"id":"2629813501","title":"港股异动 | 科伦博泰生物(06990)尾盘涨近3% 3项研究成果入选2026年ASCO年会口头汇报","url":"https://stock-news.laohu8.com/highlight/detail?id=2629813501","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629813501?lang=zh_cn&edition=full","pubTime":"2026-04-24 15:26","pubTimestamp":1777015603,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物(06990)尾盘涨近3%，截至发稿，涨2.24%，报475港元，成交额2.35亿港元。消息面上，2026年美国临床肿瘤学会(ASCO)年会将于5月29日至6月2日在美国芝加哥举行。据科伦博泰生物官微消息，公司将在本次大会公布TROP2 ADC芦康沙妥珠单抗(sac-TMT，佳泰莱®)、下一代选择性RET抑制剂富马酸仑博替尼(A400/EP0031，宁泰莱®1)以及新型ADC SKB500的三项临床研究结果，相关研究摘要全文将于当地时间2026年5月21日发布在ASCO官方网站上。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433302.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","LU0196878994.USD","06990","BK4585","BK4588","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629894566","title":"创新药概念持续拉升 海西新药(02637)领涨12.77%、歌礼制药-B(01672)涨6.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629894566","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629894566?lang=zh_cn&edition=full","pubTime":"2026-04-24 13:11","pubTimestamp":1777007494,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念午后集体持续拉升，截至发稿，海西新药 涨12.77%，歌礼制药-B涨6.27%，诺诚健华涨5.18%，信达生物涨4.10%，科伦博泰生物涨2.84%，亚盛医药-B涨2.79%。西南证券亦表示，医药生物行业近期表现虽相对疲软，估值溢价率有所下降，但行业整体仍保持一定韧性。其他生物制品、医疗研发外包和原料药等细分领域表现突出，显示出医药创新和产业链优势的持续释放。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979909","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0455707207.USD","02637","BK1589","159992","LU2097828805.USD","BK1574","LU2328871848.SGD","06990","BK1161","BK1191","LU0196878994.USD","LU2488822045.USD","01801","LU2097828631.EUR","LU2097828474.EUR","06855","LU2242644610.SGD","HK0000165453.HKD","BK1583","BK1515","LU2097828714.EUR","09969","LU0502904849.HKD","01672","01477","LU2097828557.USD","LU1969619763.USD","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629048496","title":"汇添富基金张韡旗下汇添富创新医药一季报最新持仓，重仓科伦博泰生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2629048496","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629048496?lang=zh_cn&edition=full","pubTime":"2026-04-22 19:09","pubTimestamp":1776856147,"startTime":"0","endTime":"0","summary":"证券之星消息，4月22日汇添富基金旗下张韡管理的汇添富创新医药主题混合型基金公布一季报，近1年净值增长率24.35%。与上一季度相比，该基金前十大重仓股新增信立泰，荣昌生物；其中科伦博泰生物持仓占比9.71%，为该基金第一大重仓股；热景生物，新诺威等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200046509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","09939","06990","LU0196878994.USD","BK1515","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139485201","title":"科伦博泰生物-B完成股份转换，新增8,214,278股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1139485201","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139485201?lang=zh_cn&edition=full","pubTime":"2026-04-17 19:57","pubTimestamp":1776427027,"startTime":"0","endTime":"0","summary":"四川科伦博泰生物医药股份有限公司（科伦博泰生物-B，股票代码：06990）于2026年4月17日发布公告，宣布已完成内资股与非上市外资股向H股的转换。根据公告，公司基于3,572,088股内资股及4,642,190股非上市外资股的转换，合计新增8,214,278股H股。\n本次转换发生后，H股数量由此前的162,769,979股增至170,984,257股，增幅约3.52%。同时，内资股总数由65,773,800股降至62,201,712股，非上市外资股则由4,642,190股降至0股。\n公司明确表示已遵守香港联交所证券上市规则及有关法律法规。公告由联席公司秘书周泽剑签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628205561","title":"科伦博泰生物(06990)完成H股全流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2628205561","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628205561?lang=zh_cn&edition=full","pubTime":"2026-04-17 19:51","pubTimestamp":1776426712,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物(06990)公布，合共约821.43万股内资股及非上市外资股已于2026年4月17日完成转换，且转换H股将于2026年4月20日上午九时正开始于联交所上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06990","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169202362","title":"科伦博泰生物-B2025年研发投入达31亿元，收入稳步增长但亏损扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=1169202362","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169202362?lang=zh_cn&edition=full","pubTime":"2026-04-16 23:10","pubTimestamp":1776352238,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B于报告期内继续聚焦肿瘤领域的生物制药研发，产品管线从Biotech阶段逐步向Biopharma转型。财务数据显示，2025年度公司收入约20.58亿元人民币，较2024年的19.33亿元人民币增长6.46%。总体而言，科伦博泰生物-B在2025年度实现了收入稳步上涨和业务布局的持续深化，同时研发费用的高额投入也带来了亏损的进一步扩大。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627261720","title":"中金：国家优化创新药新药上市首发价格机制 药品行业有望迎高质量发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2627261720","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627261720?lang=zh_cn&edition=full","pubTime":"2026-04-16 14:24","pubTimestamp":1776320685,"startTime":"0","endTime":"0","summary":"中金主要观点如下：优化创新药等新上市药品首发价格机制，实行新上市药品企业自评制度政策鼓励对于新上市药品价格制定，区分高水平创新药、改良新药、通用名药等情形。根据真实世界研究结果和临床使用实效，医药企业可在药品首发价格基础上适当调整价格水平。促进创新药多元支付与价格合理形成，拓宽创新药支付渠道。风险因素研发不及预期，创新药核心产品对外合作进展不及预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429285.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","06990","06978","LU2476274720.SGD","HK0000500386.USD","LU0634319403.HKD","LU0417516738.SGD","IE00B5MMRT66.SGD","LU0348766576.USD","LU0196878994.USD","LU0455707207.USD","LU0417516902.SGD","LU0348783233.USD","BK1588","01801","LU0561508036.HKD","LU0348784397.USD","01276","LU2543165471.USD","LU0307460666.USD","LU2097828714.EUR","LU2488822045.USD","LU0348825331.USD","LU1961090484.USD","LU2399975544.HKD","09926","LU2476274308.USD","LU1770034418.SGD","IPOS","LU0588546209.SGD","LU1719994722.HKD","LU0502904849.HKD","LU2097828631.EUR","LU1023057109.AUD","LU2097828557.USD","LU0540923850.HKD","LU0359202008.SGD","LU2778985437.USD","LU2097828805.USD","06160","BK1161","LU0417516571.SGD","09606","LU1794554557.SGD","LU2328871848.SGD","LU0348827113.USD","159992","BK1191","IE00B543WZ88.USD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627881282","title":"科伦博泰生物(06990)4月15日认购本金额为1亿元的浙商银行结构性存款II","url":"https://stock-news.laohu8.com/highlight/detail?id=2627881282","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627881282?lang=zh_cn&edition=full","pubTime":"2026-04-15 20:41","pubTimestamp":1776256864,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物(06990)发布公告，于2026年1月19日，本公司订立浙商银行结构性存款协议I，据此，本公司同意认购本金额为人民币2.9亿元的浙商银行结构性存款I。于2026年4月15日，本公司订立浙商银行结构性存款协议II，据此，本公司同意认购本金额为人民币1亿元的浙商银行结构性存款II。于2026年4月15日，本公司订立中国银行结构性存款协议，据此，本公司同意认购本金额为人民币3亿元的中国银行结构性存款。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601916","06990","02016","BK1560","LU0196878994.USD","BK1161","BK1231","BK0278"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627405121","title":"国办一纸文件定调药价，创新药爆发！涨停名单还在拉长","url":"https://stock-news.laohu8.com/highlight/detail?id=2627405121","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627405121?lang=zh_cn&edition=full","pubTime":"2026-04-15 14:33","pubTimestamp":1776234822,"startTime":"0","endTime":"0","summary":"政策组合拳出击","market":"sg","thumbnail":"https://img3.gelonghui.com/a401d-f3f18d25-b1d2-4d82-b91d-544aa33cb569.jpg?guru_height=718&guru_width=1280&guru_size=112216","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/a401d-f3f18d25-b1d2-4d82-b91d-544aa33cb569.jpg?guru_height=718&guru_width=1280&guru_size=112216"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4422353","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0132","BK0077","000788","000919","BK0250","BK1583","06978","LU0196878994.USD","02162","301408","BK0096","BK0185","600572","BK0197","BK0188","002589","002038","BK1574","BK0102","BK0028","BK0122","600488","BK0209","BK1587","BK0239","BK0097","BK0060","06990","159992","BK0070","BK0012","BK1161","600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101332603","title":"科伦博泰生物公布Sacituzumab Tirumotecan妇科肿瘤研究结果，亮相2026年SGO年会","url":"https://stock-news.laohu8.com/highlight/detail?id=1101332603","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101332603?lang=zh_cn&edition=full","pubTime":"2026-04-14 08:01","pubTimestamp":1776124872,"startTime":"0","endTime":"0","summary":"科伦博泰生物宣布，其SKB264-II-06/MK-2870-002研究的最新数据已在2026年妇科肿瘤学会年会上公布。该研究主要评估了Sacituzumab Tirumotecan在妇科肿瘤领域的应用效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","06990","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626818534","title":"摘“B”成功：科伦博泰生物市值破千亿港元，4月14日起简称去掉“B”","url":"https://stock-news.laohu8.com/highlight/detail?id=2626818534","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626818534?lang=zh_cn&edition=full","pubTime":"2026-04-09 18:15","pubTimestamp":1775729700,"startTime":"0","endTime":"0","summary":"4月9日，科伦博泰生物-B（06990）发布公告，宣布香港联合交易所已批准公司不再适用上市规则第18A.09至第18A.11条，自2026年4月14日起，公司中英文简称将不再加上标记“B”，新英文简称为“SKBBIO”，新中文简称为“科伦博泰生物”，公司股份代号仍为“6990”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604093699721844.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0196878994.USD","06990","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147694434","title":"科伦博泰生物-B更新2026年3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1147694434","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147694434?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:37","pubTimestamp":1775723855,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B于2026年4月9日发布截至2026年3月31日的股份变动月报。公告显示，报告期内公司未进行新增股份发行、购回或注销，整体股本维持稳定。根据公告，科伦博泰生物-B报告期末已发行普通股总数与上期保持一致。无期权与股权激励计划变动，无任何股份回购或注销活动。截至报告期末，公司股本与公眾持股比例均保持在既定要求范围内。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625944989","title":"科伦博泰生物-B(06990)H股全流通获联交所授出上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2625944989","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625944989?lang=zh_cn&edition=full","pubTime":"2026-04-08 21:06","pubTimestamp":1775653614,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B(06990)发布公告，公司已向联交所申请批准821.43万股H股(相当于根据转换及上市将予转换的公司内资股及非上市外资股总数)上市及准许买卖。董事会欣然宣布，于2026年4月2日，联交所已授出上市批准。基于截至本公告日期的公司股本总数，转换H股占公司股本总数约3.52%，因此，公司H股占公司股本总数的比例将因转换及上市完成而由69.80%增加至73.32%，内资股将由28.21%减少至26.68%，而非上市外资股将由1.99%减少至0.00%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0196878994.USD","06990","IPOS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622873003","title":"科伦博泰生物-B(06990)：中国证监会就公司H股全流通发出备案通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2622873003","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622873003?lang=zh_cn&edition=full","pubTime":"2026-03-27 23:13","pubTimestamp":1774624388,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B(06990)发布公告，公司已收到中国证监会就实施H股全流通而发出日期为2026年3月26日的备案通知书。根据备案通知书，公司就合计821.4万股内资股及非上市外资股实施H股全流通向中国证监会作出的备案已经完成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990","BK1161","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622784848","title":"【券商聚焦】西南证券维持科伦博泰生物-B(06990)“买入”评级 指","url":"https://stock-news.laohu8.com/highlight/detail?id=2622784848","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622784848?lang=zh_cn&edition=full","pubTime":"2026-03-27 14:49","pubTimestamp":1774594198,"startTime":"0","endTime":"0","summary":"金吾财讯 | 西南证券发布研报指，科伦博泰生物-B 2025年收入结构发生积极转变，药品销售收入同比大幅增长949.8%至5.43亿元人民币，占比达26.37%，标志着公司增长动力正从以授权合作收入为主，转向以自有产品商业化销售驱动。2025年为支持产品销售，销售费用同比激增160.1%至4.75亿元人民币，导致调整后年度亏损为2.11亿元，但公司在手现金及金融资产充裕，达45.59亿元。维持对公司的“买入”评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977575","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600369","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622044491","title":"【券商聚焦】招银国际维持科伦博泰(06990)“买入”评级 指2025年为向商业化转型的关键之年","url":"https://stock-news.laohu8.com/highlight/detail?id=2622044491","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622044491?lang=zh_cn&edition=full","pubTime":"2026-03-25 13:48","pubTimestamp":1774417714,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际研报指，2025年是科伦博泰 向商业化转型的关键之年，公司已从临床阶段的生物科技公司成功转型为拥有4款获批产品的生物制药企业。三大核心资产成功纳入国家医保目录，为2026年的销量增长奠定了坚实基础。该机构预计默沙东有望在2026年提交用于二线及以上子宫内膜癌的上市申请，或有望在2026年底或2027年初获批。维持“买入”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977202","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621065283","title":"高盛重申“买入”科伦博泰生物-B(06990)：芦康沙妥珠单抗OS数据表现突出 公司增长潜力持续释放","url":"https://stock-news.laohu8.com/highlight/detail?id=2621065283","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621065283?lang=zh_cn&edition=full","pubTime":"2026-03-24 18:30","pubTimestamp":1774348218,"startTime":"0","endTime":"0","summary":"高盛认为，其核心产品芦康沙妥珠单抗已成为公司增长的核心驱动力。2026年，随着产品已纳入国家医保目录，公司预计芦康沙妥珠单抗的销售将实现大幅增长，并有望在已获批适应症中成为医生首选，这部分预计将贡献超过80%的收入。此前，公司已宣布芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阳性非小细胞肺癌的III期研究已达到主要终点，进一步验证这一ADC+IO联用组合的临床价值。RDC的全球热度正在升温，科伦博泰已经提前完成卡位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"高盛重申“买入”科伦博泰生物-B(06990)：芦康沙妥珠单抗OS数据表现突出 公司增长潜力持续释放","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1868836757.USD","LU1668664300.SGD","LU2237443978.SGD","LU0196878994.USD","LU1804176565.USD","LU1894683348.USD","LU1868836591.USD","BK4550","LU0048573561.USD","LU1868837136.USD","06990","LU0096364046.USD","IE00B19Z3B42.SGD","IE00BFXG1179.USD","IE0002270589.USD","LU0345770308.USD","LU2237443382.USD","BK4585","BK4533","LU0061475181.USD","IE0004091025.USD","IE0034235188.USD","LU2750360641.GBP","LU0345770993.USD","BK4588","LU0106831901.USD","IE0004086264.USD","BK4516","LU0251131958.USD","LU1791807156.HKD","IE00BSNM7G36.USD","LU2471134796.USD","LU1868836914.USD","LU2237443465.HKD","LU2237438978.USD","LU2750360997.AUD","LU0251142724.SGD","GSX","LU2471134523.USD","BK4552","LU2471134879.HKD","IE00B19Z3581.USD","BK4127","LU2237443549.SGD","BK1161","LU2265009873.SGD","LU1894683264.USD","LU0742534661.SGD","LU2237443622.USD","LU2237443895.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621057905","title":"科伦博泰生物-B(06990)： SKB103新药临床试验申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2621057905","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621057905?lang=zh_cn&edition=full","pubTime":"2026-03-24 16:48","pubTimestamp":1774342081,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B 发布公告，本公司自主研发的新型靶向肿瘤相关抗原及免疫肿瘤学抗原的双特异性抗体偶联药物 SKB103的新药临床试验申请已获国家药品监督管理局 药品审评中心批准，用于治疗晚期实体瘤。这是本公司首个进入临床阶段的TAA-PD-L1 bsADC，也是继SKB571之后第二款进入临床阶段的用于肿瘤治疗的bsADC。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"科伦博泰生物-B(06990)： SKB103新药临床试验申请获国家药品监督管理局批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990","BK1161","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125512630","title":"科伦博泰生物-B SKB103新药临床试验申请获中国国家药监局批准用于晚期实体瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1125512630","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125512630?lang=zh_cn&edition=full","pubTime":"2026-03-24 16:47","pubTimestamp":1774342031,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B宣布，其创新药物SKB103的新药临床试验申请已正式获得中国国家药品监督管理局批准，将针对晚期实体瘤开展临床研究。此次获批标志着该药物在肿瘤治疗领域迈出关键一步，为后续研发奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06990","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621059310","title":"港股异动 | TSLP抗体疗法I期临床研究结果发表 科伦博泰生物-B(06990)涨超7% 和铂医药-B(02142)涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621059310","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621059310?lang=zh_cn&edition=full","pubTime":"2026-03-24 15:02","pubTimestamp":1774335720,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物-B、和铂医药-B午后涨幅扩大。截至发稿，科伦博泰生物涨7.34%，报426.8港元；和铂医药涨4.65%，报11.7港元。消息面上，3月23日，和铂医药宣布，HBM9378首次人体1期临床试验结果已在线发表于同行评议期刊Drug Design, Development and Therapy。公开资料显示，HBM9378由和铂医药与科伦博泰联合开发，双方共同享有其全球权益。2025年1月，和铂医药及科伦博泰与Windward Bio签订战略合作，授予后者在全球范围内对该抗体进行研究、开发、生产和商业化的独家权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417947.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","02142","VXUS","BK1574","LU0196878994.USD","06990","BK4588","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://kelun-biotech.com","stockEarnings":[{"period":"1week","weight":-0.0004},{"period":"1month","weight":-0.0872},{"period":"3month","weight":0.0938},{"period":"6month","weight":0.1237},{"period":"1year","weight":0.3614},{"period":"ytd","weight":0.1719}],"compareEarnings":[{"period":"1week","weight":0.0039},{"period":"1month","weight":0.0437},{"period":"3month","weight":-0.025},{"period":"6month","weight":-0.0011},{"period":"1year","weight":0.1567},{"period":"ytd","weight":0.0228}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四川科伦博泰生物医药股份有限公司是一家主要从事新药业务的研发、生产和销售的中国公司。该公司主要从事肿瘤学、免疫学及其他治疗领域的创新药物的研发、制造及商业化。该公司的产品有抗体药物偶联物（ADC）SKB264和A166等。该公司产品主要用于乳腺癌、非小细胞肺癌、胃肠道癌等疾病的治疗。","exchange":"SEHK","name":"科伦博泰生物","nameEN":"SKB BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦博泰生物(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦博泰生物,06990,科伦博泰生物股票,科伦博泰生物股票老虎,科伦博泰生物股票老虎国际,科伦博泰生物行情,科伦博泰生物股票行情,科伦博泰生物股价,科伦博泰生物股市,科伦博泰生物股票价格,科伦博泰生物股票交易,科伦博泰生物股票购买,科伦博泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦博泰生物(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}